Baird Medical Showcases MWA Innovations at NASOIE 2025

Baird Medical highlighted its latest microwave ablation (MWA) technology at the NASOIE 2025 Annual Meeting, engaging with clinicians and researchers on advancements in thyroid care.

Baird Medical Investment Holdings Ltd., a leader in microwave ablation (MWA) technology, showcased its latest innovations at the 2025 North American Society of Interventional Endocrinologists (NASOIE) Annual Meeting in Lehi, Utah. In a press release, the company highlighted its engagement with numerous physicians who explored the advancements in MWA technology through hands-on thyroid phantom demonstrations.

The NASOIE event, a key platform for interventional endocrinology, allowed Baird Medical to demonstrate the precision, safety, and efficiency of its MWA technology. The company's experts provided practical insights into the role of MWA in thyroid care, reinforcing Baird Medical's leadership in next-generation thyroid ablation therapies.

Baird Medical remains committed to advancing minimally invasive thyroid treatments by collaborating with medical experts and industry leaders. The insights gained from NASOIE 2025 are expected to further refine the company's MWA technology, ensuring it meets the evolving needs of thyroid care worldwide.

We hope you enjoyed this article.

Consider subscribing to one of several newsletters we publish. For example, in the Daily AI Brief you can read the most up to date AI news round-up 6 days per week.

Also, consider following our LinkedIn page AI Brief.

More from: Healthcare & Life Sciences

Subscribe to Daily AI Brief

Daily report covering major AI developments and industry news, with both top stories and complete market updates

You May Also Like